ArticleScientific reports2018

Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.

Nagako Sougawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.